ERBB2 and neoplasm: Christgen et al. compared RS and clinicopathologic prognostic factors in patients with node positive (N+) and high risk N0 ER+, HER2-negative lobular (n = 353) and non-lobular (n = 2232) BCA enrolled on the PlanB trial, and found that lobular tumors were associated with higher tumor and nodal stages, lower grade, and lower RS than non-lobular tumors, but similar disease-free survival (DFS).